Potential Protective Role of SGLT-2 Inhibitors for Chemotherapy-induced Cardiotoxicity
Status:
RECRUITING
Trial end date:
2025-04-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether dapagliflozin reduces chemotherapy-induced cardiotoxicity in participants with breast cancer treated with (neo-)adjuvant Anthracycline-based chemotherapy +/- trastuzumab. The study aims to describe the efficacy for dapagliflozin as compared to standard of care. Participants will be recruited in participating centers, where they are planning on starting (neo-) adjuvant ACT-based chemotherapy and/or trastuzumab for stage I-III breast cancer.